Specially aimed at producers and professionals associated with the salmon farming industry, the event was attended by significant exhibitors from the Pharmac’s Department of Veterinary Medical Research and Development (VMRD), Norway, Canada and Chile. They are Simen Kristofferson, Director of the Aquatic Health Department PHARMAQ Norway; Michael Ness, Aquaculture Technical Support and Account Manager Pharma Canada; Rolf Hetlid-Olsen, Principal Scientist VMRD Aquatic Health Pharmac Norway and Claudio Arcos, Technical Manager PharmacAnalytic Chile.
The importance of fish health prevention to the sustainability of the aquaculture industry were some of the topics addressed at the symposium called “Critical Aspects for Disease Prevention in the Industry” and which was organized by PharmC, of Zoetis. Part, -Through PHARMAQademy- Last Thursday in Puerto Varas.
“Pharm, in its constant quest to provide the best products and services to growers, wanted to organize this symposium with the aim of reviewing the aspects that affect the good results of our products. For many years we have focused on productivity, animal welfare and aquatic We have studied and developed products for problems affecting the sustainability of the agricultural industry, especially for salmon production,” said Julio Mendoza, manager of PHARMAQ Chile.
He added that “both producers and professionals from the field invited to this symposium showed great interest in being able to hear their questions about our products, especially our vaccines. Cross-protection, the increasing use of antibiotics (which generates growth in resistant Rickettsia strains), measurement of the cellular immune response (where there is still no specific technology for our vaccine) and other issues, among others. The VMRD team was able to respond. We believe these examples are important and now that it is possible to meet in person, we will continue to create more of these meetings and technical seminars with our team of experts”, the company’s manager told.
It was also an opportunity to provide an update and background on Pharmac’s vaccination strategies. In this sense, relevant was the presentation of Simen Kristoffersson, Director of Aquatic Health Department Pharma Norway, “Introduction to the R&D sector of the Pharmac part of Zoetis”, “Development of Alpha JECT® Livac SRS Live”. Vaccines and Good Use Methods” and “Cross-Protection Provided by Alpha JECT® LiVac SRS Vaccine”.
“It is important to remember that Alpha Jet® Livac SRS is a live vaccine and the bacteria in the vaccine must be alive for the desired effect. The use of good practices of use, such as maintaining the cold chain, rapid thawing, adequate reconstitution and injection Maintaining the recommended water temperature at the time of vaccination and during the immunity period will ensure that the bacteria in the fish are alive and a specific immune response is generated. The health status of the fish is also very important for the effectiveness of the vaccine and diseased fish should never be vaccinated. Furthermore, fish should not be vaccinated during the smelting process,” explained Kristofferson.
In this regard, during the presentation he also pointed out that “For Alpha JECT LIVac® SRS, the best way to achieve the expected efficacy of the vaccine is to ensure good practices during vaccination and respect the period of post-vaccination immune development.” (456) UTA).. Efficacy is best monitored by measuring the reduction in mortality after an SRS outbreak, estimating this reduction in mortality by the SRS of the fish population for each production cycle over time. This is done by monitoring the condition. It is important that proper diagnosis is used to draw conclusions on the cause of death so that fish with other diseases are not classified as having SRS. Since ALPHA JECT® LiVac SRS A live vaccine, it activates other parts of the immune system than classic inactivated vaccines.For example, fish vaccinated with ALPHA JECT® LiVac SRS will exhibit a significantly lower specific antibody response than inactivated SRS vaccines but we Found significantly better protection against disease mortality. Therefore, the specific measure of vaccine efficacy for inactivated vaccines cannot be applied for Alpha JECT® LiVac SRS”, said the director of the Norwegian Department of Aquatic Health.
The day of presentations continued with talks with Rolf Hetlid-Olsen Principal Scientist VMRD Aquatic Health Pharma Norway on “Relevant Aspects on the Efficacy of Alpha JCT® Livac SRS” and “Efficacy of Alpha JCT® Livac SRS Vaccine in Combination with Alpha JECT®” . Micro 4-2″.
As explained by Rolf Hetlid-Olsen “The combination of Alpha Jet® Livac SRS and Alpha JECT® Micro 4-2 has only been available for a little over a year and therefore results in field use have been limited. But so far We are very pleased that we have seen similar overall and similar results to the protection provided by our current strategy of ALPHA JECT® LiVac SRS + ALPHA JECT® 5-1. There were no reports of lack of efficacy or safety issues This is a confirmation of the results observed in laboratory studies where the combination has shown high efficacy and an excellent safety profile in challenge studies,” he said.
With regard to the response to the use of this vaccination strategy, they stated that “Producers have shown good reception of our new vaccination strategy with Alpha JECT® LiVac SRS, are ready to continue using our product throughout their production cycle and As a team at Pharmac, we are convinced that it is important to continue to document experiences in the field and to continue evaluating the various benefits associated with the use of microdose vaccines”, said Hetlid-Olsen.
It was then the turn of Michael Ness, Aquaculture Technical Support and Account Manager PHARMAQ Canada’s presentation “Experience in the use of vaccines in micro-dose”, and later Claudio Arcos, Technical Manager PHARMAQ Analytical Chile, who reported on the “optimized program”. Isolation for P. Salmonis”.
At the end of the symposium, a forum was held with all the exhibitors, which allowed the exchange of experiences and ideas between panelists and attendees, which is evidence of the inspiration for Pharmac’s vaccination strategies and disease prevention in the industry .